A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually

Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually

5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding

Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally